MIM
CRVS icon

MetLife Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

MetLife Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$484K Buy
33,100
+2,318
+8% +$37K ﹤0.01% 1764
2025
Q4 		$237K Sell
30,782
-2,812
-8% -$22.2K ﹤0.01% 2191
2025
Q3 		$248K Buy
33,594
+1,503
+5% +$7.69K ﹤0.01% 2196
2025
Q2 		$128K Buy
+32,091
New +$117K ﹤0.01% 2410

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MetLife Investment Management's CRVS Position: Q1 2026 in Review

MetLife Investment Management increased its Corvus Pharmaceuticals (CRVS) stake by 7.5% in Q1 2026, buying an estimated $37K and bringing the position to 33,100 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #1764.

MetLife Investment Management first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • MetLife Investment Management held 33,100 shares of Corvus Pharmaceuticals worth $484K as of Q1 2026.
  • MetLife Investment Management bought 2,318 Corvus Pharmaceuticals shares in Q1 2026, an estimated $37K.
  • Corvus Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1764 holding.
  • MetLife Investment Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.